Keane T - Search Results

1

RNA expression differences in prostate tumors and tumor-adjacent stroma between Black and White Americans.

Rahmatpanah F, Robles G, Lilly M, Keane T, Kumar V, Mercola D, Randhawa P, McClelland M. Rahmatpanah F, et al. Among authors: keane t. Oncotarget. 2021 Jul 20;12(15):1457-1469. doi: 10.18632/oncotarget.28024. eCollection 2021 Jul 20. Oncotarget. 2021. PMID: 34316327 Free PMC article.

2

The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy.

Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, Turner LS, Cheng J, Bielawska A, Bielawski J, Keane TE, Obeid LM, Hannun YA, Norris JS, Liu X. Saad AF, et al. Cancer Biol Ther. 2007 Sep;6(9):1455-60. doi: 10.4161/cbt.6.9.4623. Epub 2007 Jun 23. Cancer Biol Ther. 2007. PMID: 17881906

3

Managing prostate cancer: the role of hormone therapy.

Ramirez ML, Keane TE, Evans CP. Ramirez ML, et al. Can J Urol. 2007 Dec;14 Suppl 1:10-8. Can J Urol. 2007. PMID: 18163939 Review.

4

Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.

Varela JC, Atkinson C, Woolson R, Keane TE, Tomlinson S. Varela JC, et al. Int J Cancer. 2008 Sep 15;123(6):1357-63. doi: 10.1002/ijc.23676. Int J Cancer. 2008. PMID: 18561323 Free PMC article.

5

Salvage options for biochemical recurrence after primary therapy for prostate cancer.

Bong GW, Keane TE. Bong GW, et al. Can J Urol. 2007 Dec;14 Suppl 1:2-9. Can J Urol. 2007. PMID: 18163938 Review.

6

Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.

Greiman AK, Keane TE. Greiman AK, et al. Curr Urol Rep. 2017 Jun;18(6):41. doi: 10.1007/s11934-017-0688-5. Curr Urol Rep. 2017. PMID: 28417429 Review.

7

Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer.

Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, Bai A, Gault CR, McPherson AS, Garcia N, Beckham TH, Saad A, Bielawska A, Bielawski J, Hannun YA, Keane TE, Taha MI, Hammouda HM, Norris JS, Liu X. Mahdy AE, et al. Mol Ther. 2009 Mar;17(3):430-8. doi: 10.1038/mt.2008.281. Epub 2008 Dec 23. Mol Ther. 2009. PMID: 19107118 Free PMC article.

8

Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.

Bong GW, Clarke HS Jr, Hancock WC, Keane TE. Bong GW, et al. Urology. 2008 Jun;71(6):1177-80. doi: 10.1016/j.urology.2007.09.066. Epub 2008 Feb 15. Urology. 2008. PMID: 18279929

9

Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy.

Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, Keane TE, Hannun YA, Norris JS. Liu X, et al. Expert Opin Ther Targets. 2009 Dec;13(12):1449-58. doi: 10.1517/14728220903357512. Expert Opin Ther Targets. 2009. PMID: 19874262 Free PMC article. Review.

10

The multi-disciplinary management of high-risk prostate cancer.

Picard JC, Golshayan AR, Marshall DT, Opfermann KJ, Keane TE. Picard JC, et al. Among authors: keane te. Urol Oncol. 2012 Jan-Feb;30(1):3-15. doi: 10.1016/j.urolonc.2009.09.002. Epub 2009 Nov 27. Urol Oncol. 2012. PMID: 19945310 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

657 results

Search Page